EPIDERMAL GROWTH FACTOR RECEPTOR OVEREXPRESSION IN TRIPLE NEGATIVE BREAST CANCER

Main Article Content

Ayesha Safdar
Maria Khan
Raazia Mahmood
Faryal Javaid
Ayesha Sajjad
Maria tasneem khattak
Iqbal Muhammad khan

Abstract

Objective: To observe the frequency of EGFR overexpression and its correlation with clinicopathological parameters in patients diagnosed with triple negative breast carcinoma.
Methodology: This Cross-sectional study was conducted at Rehman Medical Institute from June 2022 to June 2023. Biopsy specimen of 41 female patients diagnosed with triple negative breast carcinoma (TNBC) were received in histopathology department. Specimen underwent eosin and hematoxylin staining and immunohistochemistry analysis. Demographic characteristics and histopathological parameters were recorded.
Results: Mean age of the participants was 46.27 ± 3.75 years. Axillary metastasis was observed in 24 (58.5%) patients while perinodal extension was observed in 05 (12.2%) patients. Immunohistochemistry analysis revealed 23 (56.1%) EGFR positive specimens while 18 (43.9%) specimens were EGFR negative. Out of 23 patients with axillary metastasis the frequency of EGFR positive carcinomas was 17 (73.9%) which was significantly greater than 06 (26.1%) patients exhibiting negative EGFR expression. Frequency of EGFR positive expression was significantly
increased with higher grade and stage of the tumor (p-value <0.05).
Conclusion: EGFR overexpression in Triple negative breast carcinoma is associated with poor clinicopathological indicators which leads to poor prognosis.

Article Details

How to Cite
1.
Safdar A, Khan M, Mahmood R, Javaid F, Sajjad A, Khattak DMT, Muhammad khan I. EPIDERMAL GROWTH FACTOR RECEPTOR OVEREXPRESSION IN TRIPLE NEGATIVE BREAST CANCER. J Postgrad Med Inst [Internet]. 2024 May 8 [cited 2024 Jul. 13];38(2):140-4. Available from: https://jpmi.org.pk/index.php/jpmi/article/view/3329
Section
Original Article
Author Biography

Maria tasneem khattak, Rehman Medical Institute

Associate Professor and Consultant Histopathologist, Rehman Medical Institute/Rehman College of Dentistry (RMI/RCD), Peshawar

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. DOI:10.3322/caac.21660.

Abbas G, Shah S, Hanif M, Asghar A, Shafique M, Ashraf K. Cancer prevalence, incidence and mortality rates in Pakistan in 2018. Bull Cancer. 2020;107(4):517-8. DOI:10.1016/j.bulcan.2019.12.011.

Zagami P, Carey LA. Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer. 2022 Aug 20;8(1):95. DOI:10.1038/s41523-022-00468-0

Jitariu AA, Cîmpean AM, Ribatti D, Raica M. Triple negative breast cancer: the kiss of death. Oncotarget. 2017;8(28):46652. DOI: 10.18632/oncotarget.16938

Dass SA, Tan KL, Selva Rajan R, Mokhtar NF, Mohd Adzmi ER, Rahman WF, et al. Triple negative breast cancer: A review of present and future diagnostic modalities. Medicina. 2021;57(1):62. DOI: 10.3390/medicina57010062.

Ullah MF. Breast cancer: current perspectives on the disease status. Breast Cancer Metastasis and Drug Resistance: Challenges and Progress. Breast Can Met Drug Resist. 2019:51-64. DOI: 10.1007/978-3-030-20301-6_4

Maennling AE, Tur MK, Niebert M, Klockenbring T, Zeppernick F, Gattenlohner S et al. Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials. Cancers. 2019;11(12):1826. DOI: 10.3390/cancers11121826

Talukdar S, Emdad L, Das SK, Fisher PB. EGFR: an essential receptor tyrosine kinase-regulator of cancer stem cells. Adv Cancer Res. 2020;147:161-88. DOI: 10.1016/bs.acr.2020.04.003.

Oshi M, Gandhi S, Tokumaru Y, Yan L, Yamada A, Matsuyama R, et al. Conflicting roles of EGFR expression by subtypes in breast cancer. Am J Cancer Res. 2021;11(10):5094.

Zakaria Z, Zulkifle MF, Hasan WA, Azhari AK, Raub SH, Eswaran J, et al. Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort. Onco Targets Ther. 2019;12:8-16. DOI: 10.1097/PPO.0000000000000500.

Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J. 2021;27(1):8-16. DOI: 10.1097/PPO.0000000000000500

Munawar S, Haider R, Ali SM, Yaqeen SR, Islam S, Asghar IA et al. Triple-negative metaplastic breast carcinoma: association of epidermal growth factor receptor expression with prognostic parameters and clinical outcome. Cureus. 2021;13(5). DOI: 10.7759/cureus.15006.

Hashmi AA, Naz S, Hashmi SK, Irfan M, Hussain ZF, Khan EY et al. Epidermal growth factor receptor (EGFR) overexpression in triple-negative breast cancer: association with clinicopathologic features and prognostic parameters. Surg Exp Pathol. 2019; 2(1);1-7. DOI:10.1186/s42047-018-0029-0.

Sajid MT, Ahmed M, Azhar M, Mustafa Q, Shukr I, Kamal Z. Age-related frequency of triple negative breast cancer in women. J Coll Physicians Surg Pak. 2014;24(6):400-3.

Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Onco. 2015;33(1):13. DOI: 10.1200/JCO.2014.57.0572.

Jiang W, Wang X, Zhang C, Xue L, Yang L. Expression and clinical significance of MAPK and EGFR in triple negative breast cancer . Onco Letters. 2020;19(3):1842-8. DOI: 10.3892/ol.2020.11274.

Maqbool M, Bekele F, Fekadu G. Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer Ther. 2022:15-24. DOI: 10.2147/BCTT.S348060.

Uribe ML, Marrocco I, Yarden Y. EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance. Cancers. 2021;13(11):2748. DOI: 10.3390/cancers13112748.

Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer-Expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91-113. DOI: 10.1038/s41571-021-00565-2.

Liu Y, Zhou Y, Huang KH, Li Y, Fang X, An L, et al. EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC. Aging (Albany NY). 2019;11(23):11054. DOI: 10.18632/aging.102510.

Lev S. Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis. Biochem Spc Trans. 2020;48(2):657-65. DOI: 10.1042/BST20191055.